An interventional study of condensed RT group and distributed RT group in Stroke and Hemiplegia, Spastic, sponsored by Chang Gung Memorial Hospital. Completed at 1 site in Taiwan. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2020-06-23.
Sponsored by Chang Gung Memorial Hospital · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 88 studies in Stroke by Chang Gung Memorial Hospital — 13 open to participants now, 13 under way, none of them phase 3. Stroke · Chang Gung Memorial Hospital.
Among the 88 studies in Stroke by Chang Gung Memorial Hospital, this one is the 57th largest by enrollment of the 82 interventional ones that give a count, is one of 7 that started in 2017, is one of 71 with no phase, and was the 44th registered.
8,268 studies on the registry are indexed under Stroke; 2,062 are open to participants now.
Browse Stroke studies →13 of the 88 studies in Stroke by Chang Gung Memorial Hospital are open now, in 1 country. Recruiting first, the newest first:
Chang Gung Memorial Hospital · Sites in Taiwan
Ages 20–80
Chang Gung Memorial Hospital · Sites in Taiwan
Ages 20+ · Healthy volunteers
Chang Gung Memorial Hospital · Sites in Taiwan
Ages 40–80
Chang Gung Memorial Hospital · Sites in Taiwan
Ages 18–75
Chang Gung Memorial Hospital · Sites in Taiwan
Ages 20–75
By country, each count listing its studies:
Of the 1,418 Stroke studies recruiting now, 696 (49%) set no upper age limit and 282 (20%) stop at 75 or younger; 77 take children under 18; 196 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
88 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 2 6 · Phase 3 6
First in 2007; this study’s year is marked. 7 started in 2017.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 36 is below the median of 49 across 6,036 interventional studies indexed under Stroke.
Median enrollment 55 across the 82 interventional studies, 120 across the 6 observational. Of the 49 that completed or were terminated, 1 (2%) have results posted.
This tab as a report to print or save as PDF → With an account.
Chang Gung Memorial Hospital is the lead sponsor of 1,096 studies on the registry; 239 are open to participants now.
5 of the studies in Stroke by Chang Gung Memorial Hospital that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06204744Chang Gung Memorial HospitalHome-based Arm and Hand Exercise Program for Stroke: A Multisite Trial | 2026-12 |
| NCT06258538Chang Gung Memorial HospitalEffects of Circuit Training Combining Different Types of Distal Robot-assisted and Task-oriented Therapy on Motor Control, Motor and Daily Functions, and Quality of Life After Stroke | 2026-12-31 |
| NCT05238272Chang Gung Memorial HospitalNovel Brain Neurotechnology for Optimizing Precision Mirror Therapy in Stroke | 2026-12-31 |
| NCT05903235Chang Gung Memorial HospitalMixed Reality and Virtual Reality Technology With Mirror Therapy for Stroke Rehabilitation | 2027-07-31 |
| NCT07054424Chang Gung Memorial HospitalRepetitive Transcranial Magnetic Stimulation Combined With Bimanual Therapy for Upper Limb Stroke Rehabilitation | 2027-07-31 |
Add all 5 to your calendar (.ics) → With an account.
Among the 88 studies in Stroke by Chang Gung Memorial Hospital, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this project is to examine and compare the immediate and long-term effects of combined Botulinum toxin type A (BoNT-A) injection between condensed and distributed robot-assisted training (RT) programs in patients with spastic hemiplegic stroke. Spasticity, a common impairment after stroke, has a profound impact on activity and participation for patients. According to the result of the investigator's ongoing study, the investigators found BoNT-A injection combined with robot-assisted training is recommended to enhance functional recovery for patients with spastic hemiplegic stroke. However, the optimal program as considering the RT frequency is unknown.
The aims of this study are to determine and compare the immediate and longer-term effects between condensed and distributed programs of RT following BoNT-A injection in subjects with spastic hemiplegic stroke .
Participants with chronic spastic hemiplegic stroke will be recruited and randomly assigned to either condensed or distributed RT groups post BoNT-A injection. Each training session included 40 minutes RT, followed by 40-minute functional training. The condensed group will receive 4 sessions per week, for 6 weeks, the distributed group 2 sessions per week, for 12 weeks. Body function and structures outcome measures include Fugl-Meyer Assessment, Modified Ashworth Scale. Activity and participation measures include Wolf Motor Function Test, Motor Activity Log, and Canadian Occupational Performance Measure. In addition, to directly reflect a patient's unique needs and goals, Goal Attainment Scaling will be assessed. Evaluators will be blind to group allocation. The outcome will be measured at pre-treatment, post-treatment, and 6-week follow-up. The investigators will also use the movement time of robot without powered assistance and surface EMG to determine the motor learning processes of patients receiving the two practice frequencies of RT.
This comparative efficacy study will be the first to examine and compare the motor learning processes and immediate and long-term effects between condensed and distributed RT post BoNT injection. The results may provide clinicians with the appropriate methods to scheduling RT following BoNT-A injection to improve upper limb functions for patients with hemiplegic spasticity stroke.
Patients with spasticity are thought to have greater levels of disability, poorer quality of life, and more caregiver burden than patients without spasticity. Thus, the treatment of spasticity, particularly of the upper limb, is one of the important issues in post-stroke rehabilitation. Botulinum toxin A (BoNT-A) injection becomes the most widely used for managing focal spasticity.(de Paiva, Meunier, Molgo, Aoki, \& Dolly, 1999) There was a large body of evidence supporting the efficacy of BoNT-A on post-stroke spasticity (Bhakta, Cozens, Chamberlain, \& Bamford, 2000; Elia, Filippini, Calandrella, \& Albanese, 2009). However, the effect of BoNT on active function remains uncertain (Foley et al., 2013; Sheean, 2001). Patients with spasticity might use abnormal motor program to perform their movements. Once the spasticity is reduced by BoNT-A, the established abnormal program could no longer direct the movement execution, resulting in difficulty in performing movement or task. Evidence-based behavioral approaches with accurate sensorimotor input post BoNT-A injection programs might help patients relearn motor control and reestablish correct motor program, and, thus, optimize spasticity treatment outcomes. Robotic therapy (RT) has been proved effective in patients with moderate and severe arm weakness after stroke. RT is a novel approach to stroke rehabilitation that uses intensive, repetitive, interactive, and individualized practice as an optimal strategy to enhance motor learning. (Mirelman A, Bonato P, Deutsch JE. Effects of training with a robot virtual reality system compared with a robot alone on the gait of individuals after stroke. Stroke. 2009;40:169 -174. 5. Brewer BR, McDowell SK, Worthen-Chaudhari LC. Poststroke upper extremity rehabilitation: a review of robotic systems and clinical results. Top Stroke Rehabil. 2007;14:22- 44). An increasing number of efficacy studies have shown that RT had positive impacts on upper limbs motor function and strength in stroke survivors (Hsieh et al., 2016; Hung et al., 2016; Kwakkel, Kollen, \& Krebs, 2008; Mehrholz, Platz, Kugler, \& Pohl, 2009; Prange, Jannink, Groothuis-Oudshoorn, Hermens, \& IJzerman, 2006). One study that investigated the effectiveness of BoNT-A injection combined with RT (Pennati, Da Re, Messineo, \& Bonaiuti, 2015) showed that the hybrid approach reduces spasticity and improved motor performance in patients with chronic stroke. The key element leading to effective intervention for RT is the high-intensity, repetitive, task-specific practices. As well as treatment intensity, the scheduling of training is also shown to influence skills acquisition. Massed practice refers to a practice schedule that allows no periods of rest in between practice, whereas distributed practice refers to a schedule where periods of practice are interspersed with periods of rest (Verdaasdonk, Stassen, Van Wijk, \& Dankelman, 2007). Distributed practice has been demonstrated to benefit complex psychomotor skills acquisition in motor learning,(Mackay, Morgan, Datta, Chang, \& Darzi, 2002) including skills transfer. In order to develop the optimal RT schedule following BoNT-A injection, we should consider the duration of BoNT-A effect. It was known that the antispastic effect of one BoNT-A injection usually lasted for 3-4 months, and the effect tended to decrease since 2 months post-injection. When provided in a fixed dosage, we did not know should we condense the training program within 2 months post-injection, when there was great effect of BoNT-A, or distribute the training program within 4 months to across the whole effective period of BoNT-A. Therefore, the aims of this study are to determine and compare the immediate / maintained effects between condensed and distributed training programs of RT following BoNT-A injection in subjects with spastic hemiplegic stroke.
Participants with stroke will be recruited from a rehabilitation department of tertiary referral hospital. Patients who have spastic hemiplegic stroke are screened for eligibility to join the study. The inclusion criteria are: (1) clinical and imagine diagnosis of a first or recurrent unilateral stroke ≥ 6 months; (2) upper limb spasticity (modified Ashworth scale of ≥ 1+ for elbow flexor and/or forearm pronator and/or finger flexor and/or wrist flexor muscles (Bohannon \& Smith, 1987); (3) initial motor part of UE of FMA score ranging from 13 to 56, indicating moderate to severe movement impairment (Duncan, Goldstein, Matchar, Divine, \& Feussner, 1992; Fugl Meyer, Jaasko, \& Leyman, 1975; Park, Wolf, Blanton, Winstein, \& Nichols-Larsen, 2008); (4) no serious cognitive impairment (i.e., Mini Mental State Exam score > 20) (Teng \& Chui, 1987); (5) age ≥ 18 years ; and (6) willing to provide written informed consent. Participants are excluded if they are pregnant, or with bilateral hemispheric or cerebellar lesions, sever aphasia, significant visual field deficits or hemineglect, contraindication for BoNT-A injection, treatment with BoNT-A within 4 months before recruitment, any fixed joint contracture of the affected upper limb, or a history of orthopedic or other neurological diseases and/or medical conditions that would prevent adherence to the rehabilitation protocol. To minimize possible confounding effects of upper limb motor ability, we will stratify participants into groups based on upper limb motor function (FMA UE score: 13-40 or a FMA UE score: 41-56) (Luft et al., 2004; Thielman, Kaminski, \& Gentile, 2008). Intervention BoNT-A injections Injections are administered at baseline by 1 of 2 senior rehabilitation physicians who have more than 10 years of experience of BoNT-A injection. Doses and muscles selected for BoNT-A injection are individualized on the basis of the spasticity patterns, severity of spasticity, and treatment goals. Botox brand BoNT-A Purified Neurotoxin Complex, (Allergan Pharmaceuticals, Irvine, CA) is used in this study. Location of the targeted muscle is confirmed by using echo guide. After injection with BoNT-A, patients will receive different frequency schedule of treatment according to their group allocation. Participants in the condensed group receive 4 sessions per week for 6 weeks and participants in the distributed practice group attende 2 sessions per week for 12 weeks. During each session, participants receive 45 minutes of repetitive RT with the InMotion 2.0 robot (Interactive Motion Technologies Inc., Watertown, MA), followed by 30 minutes of transition-to-task practice. The outcome measures were in accordance with the International Classification of Functioning, Disability and Health (ICF) framework published by the World Health Organization World Health. Body function and structures outcome measures include Fugl-Meyer Assessment (FMA), Modified Ashworth Scale(Masiero et al., 2006). Activity and participation measures include Wolf Motor Function Test (WMFT), Motor Activity Log (MAL), Canadian Occupational Performance Measure (COPM) and Goal attainment scale (GAS). Evaluators are blind to group allocation. The outcomes are measured at 4 time points: before intervention, mid- intervention, post intervention, and 6 weeks after intervention, except the MAL which is measured before intervention, post intervention, and 6 weeks after intervention. Body function and structures measures Fugl-Meyer Assessment (FMA) The upper-extremity (UE) subscale of the FMA is used to assess neuromusculoskeletal and movement related functions. It consists of 33 upper extremity items for the reflexes and movement of shoulder, elbow, forearm, wrist, hand, and coordination/speed. They are scored on a 3-point ordinal scale (0-cannot perform, 1-performs partially, 2-performs fully)(Fugl Meyer et al., 1975). Higher score indicates better motor function of UE, and the maximum score is 66. Satisfactory psychometric properties of the FMA have been demonstrated(Platz et al., 2005) Modified Ashworth Scale (MAS) Spasticity of skeletal muscle in upper extremity is evaluated by using the MAS scale (Bohannon \& Smith, 1987). It uses a 6-point scale to score the resistance to passive movement for each join with higher score indicating higher spasticity. The MAS has shown good reliability and validity (Pandyan et al., 1999). Activity and participation measures Wolf Motor Function Test (WMFT) The WMFT is a quantitative measure of upper extremity motor ability through timed and functional tasks (Uswatte, Taub, Stuss, Winocur, \& Robertson, 1999). The WMFT includes 17 tasks (15 function-based and 2 strength-based). Performances were timed and rated by using a 6-point ordinal scale. The WMFT has good interrater reliability and criterion validity in patients with UE hemiparesis (Morris, Uswatte, Crago, Cook, \& Taub, 2001) . Motor Activity Log (MAL) The MAL is a semi-structured interview to rate how well [quality of movement scale (QOM)] and how much [amount of use scale (AOU)] they use their affected upper extremity in 30 daily activities using a 6-point scale (Uswatte, Taub, Morris, Light, \& Thompson, 2006). Higher scores represent better performance. The MAL has established reliability, validity, and responsiveness in patients with stroke(Uswatte et al., 2006; Uswatte, Taub, Morris, Vignolo, \& McCulloch, 2005; Van der Lee, Beckerman, Knol, De Vet, \& Bouter, 2004). Canadian Occupational Performance Measure (COPM) The COPM, a semi-structured interview, will be used to assess a participant's perception of the performance in the areas of self-care, productivity and leisure (Dedding, Cardol, Eyssen, \& Beelen, 2004). The COPM can capture information about activities that the participant wants, needs or is expected to perform. The participant is asked to rate five most important activities on a 10-point scale for performance, ranging from 1 (not at all able) to 10 (able to perform extremely well), and for satisfaction, ranging from 1 (not at all satisfied) to 10 (extremely satisfied)(Dedding et al., 2004). The COPM is a reliable, valid, and responsive outcome measure for practitioners and researchers (Carswell et al., 2004). Goal attainment scale (GAS) The GAS is a useful measure of participants' individual goals that could be achieved in the course of intervention (L. Turner-Stokes, 2009). In the first session, the therapist will discuss with the participants and their families to define the goals. Each goal is rated on a 5-point scale ranging from -2 to +2 in the last session. The GAS enables the data to be placed on a quantitative measurement scale and can be helpful for qualitative interpretation (L. Turner-Stokes, 2009). Evidence of validity and responsiveness for the GAS was reported in previous studies(Gordon, Powell, \& Rockwood, 1999; Rockwood, Stolee, \& FoxP, 1993) Data Analysis Data are analyzed with PASW statistics 18 (SPSS Inc, Chicago, IL, USA). To examine the baseline differences among three groups, the chi-square test is used for categorical data and student t tests for continuous variables. We use mixed ANOVA to test the within subject effect of time (4 measurement time points: pre-test, mid-test, post-test, follow-up) and to test the between subject effect of group (two treatment groups: condensed treatment and distributed treatment) and to test interaction effect between time and group. Pair wise comparison with Bonferroni adjustments is used to examine the differences between measurement time points.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
MMSE and MoCA
Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Training session included 45 minutes RT, followed by 30-minute functional training. The condensed group will receive 4 sessions per week, for 6 weeks.
Device: condensed RT group
Training session included 45 minutes RT, followed by 30-minute functional training. The distributed group 2 sessions per week, for 12 weeks.
Device: distributed RT group
BoNT-A injections Botox brand BoNT-A Purified Neurotoxin Complex, (Allergan Pharmaceuticals, Irvine, CA) will be prepared by diluting lyophilized toxin with 0.9% saline to a concentration of 33-100 U/ml. depending on the size of the target muscle. Location of the targeted muscle will be confirmed by using echo guide. Training procedures There are total 24 training sessions following one week after injection. Participants in the condensed practice group will receive 4 sessions per week, for 6 weeks. During each practice session, participants first receive 40 minutes of repetitive RT with the InMotion 3.0 robot (Interactive Motion Technologies Inc., Watertown, MA), followed by 40 minutes of transition-to-task practice.
Also known as: botulinum toxin injection, InMotion 3.0 robot (Interactive Motion Technologies Inc., Watertown, MA)
BoNT-A injections Botox brand BoNT-A Purified Neurotoxin Complex, (Allergan Pharmaceuticals, Irvine, CA) will be prepared by diluting lyophilized toxin with 0.9% saline to a concentration of 33-100 U/ml. depending on the size of the target muscle. Location of the targeted muscle will be confirmed by using echo guide. Training procedures There are total 24 training sessions following one week after injection. Participants in the condensed practice group will receive 2 sessions per week, for 12 weeks. During each practice session, participants first receive 40 minutes of repetitive RT with the InMotion 3.0 robot (Interactive Motion Technologies Inc., Watertown, MA), followed by 40 minutes of transition-to-task practice.
Also known as: botulinum toxin injection, InMotion 3.0 robot (Interactive Motion Technologies Inc., Watertown, MA)
Fugl-Meyer Assessment (FMA)
The upper-extremity (UE) subscale of the FMA will be used to assess neuromusculoskeletal and movement related functions. It consists of 33 upper extremity items for the reflexes and movement of shoulder, elbow, forearm, wrist, hand, and coordination/speed. They are scored on a 3-point ordinal scale (0-cannot perform, 1-performs partially, 2-performs fully)(Fugl Meyer et al., 1975). Higher score indicates better motor function of UE. The maximum score is 66, and the minimum score is 0. Satisfactory psychometric properties of the FMA have been demonstrated(Hsueh \& Hsieh, 2002;Platz et al., 2005). The outcome will be measured at 4 time points: 1 week before intervention, 5 weeks after injection (in the middle of intervention), 1 week after intervention (post-intervention), 6 weeks after intervention.
Time frame: assessed at 1 week before intervention, 5 weeks after injection (in the middle of intervention), 1 week after intervention (post-intervention), 6 weeks after intervention., change from baseline at 1.5 months reported
Wolf Motor Function Test (WMFT)-Time
The WMFT is a quantitative measure of upper extremity motor ability through timed and functional tasks. The WMFT includes 17 tasks (15 function-based and 2 strength-based). In this study only 15 function-based tasks were used. Performances were timed and rated by using a 6-point ordinal scale ranging from 0 to 5 ,There are 2 different scores: the WMFT -Time (time required to complete the tasks) and WMFT -FAS (functional Ability Scale, where a score of 6 points is used to assess the functional capacity of each task: 0 indicating that the patient cannot attempt the task, and 5 where the movement seems normal) The item ratings and time are summed respectively, and the average item rating and time are reported.The minimum value of mean FAS is 0, maximum 5, the higher the better. The outcome will be measured at 4 time points: 1 week before intervention, 5 weeks after injection (in the middle of intervention), 1 week after intervention (post-intervention), 6 weeks after in
Time frame: assessed at 1 week before intervention, 5 weeks after injection (in the middle of intervention), 1 week after intervention (post-intervention), 6 weeks after intervention., change from baseline at 1.5 months reported
Modified Ashworth Scale (Masiero et al.)
Spasticity of skeletal muscle in upper extremity will be evaluated by using the MAS scale (Bohannon \& Smith, 1987). It uses a 6-level scale to score the average resistance to passive movement for each join with higher score indicating higher spasticity. The MAS has shown good reliability and validity (Pandyan et al., 1999). The maximum of MAS scale is 4, and the minimum is 0. The outcome will be measured at 4 time points: 1 week before intervention, 5 weeks after injection (in the middle of intervention), post intervention, 6 weeks after intervention.
Time frame: assessed at 1 week before intervention, 5 weeks after injection (in the middle of intervention), 1 week after intervention (post-intervention), 6 weeks after intervention., change from baseline at 1.5 months reported
Wolf Motor Function Test (WMFT)-Function
The WMFT is a quantitative measure of upper extremity motor ability through timed and functional tasks. The WMFT includes 17 tasks (15 function-based and 2 strength-based). In this study only 15 function-based tasks were used. Performances were timed and rated by using a 6-point ordinal scale ranging from 0 to 5 ,There are 2 different scores: the WMFT -Time (time required to complete the tasks) and WMFT -FAS (functional Ability Scale, where a score of 6 points is used to assess the functional capacity of each task: 0 indicating that the patient cannot attempt the task, and 5 where the movement seems normal) The item ratings and time are summed respectively, and the average item rating and time are reported.The minimum value of mean FAS is 0, maximum 5, the higher the better. The outcome will be measured at 4 time points: 1 week before intervention, 5 weeks after injection (in the middle of intervention), 1 week after intervention (post-intervention), 6 weeks after in
Time frame: assessed at 1 week before intervention, 5 weeks after injection (in the middle of intervention), 1 week after intervention (post-intervention), 6 weeks after intervention., change from baseline at 1.5 months reported
Canadian Occupational Performance Measure (COPM)
The COPM, a semi-structured interview, will be used to assess a participant's perception of the performance in the areas of self-care, productivity and leisure (Dedding, Cardol, Eyssen, \& Beelen, 2004). The COPM can capture information about activities that the participant wants, needs or is expected to perform. The participant will be asked to rate five most important activities on a 10-point scale for performance, ranging from 1 (not at all able) to 10 (able to perform extremely well), and for satisfaction, ranging from 1 (not at all satisfied) to 10 (extremely satisfied)(Dedding et al.,2004). The COPM is a reliable, valid, and responsive outcome measure for practitioners and researchers (Carswell et al., 2004). The outcome will be measured at 4 time points: 1 week before intervention, 5 weeks after injection (in the middle of intervention), 1 week after intervention (post-intervention), 6 weeks after intervention.
Time frame: assessed at 1 week before intervention, 5 weeks after injection (in the middle of intervention), 1 week after intervention (post-intervention), 6 weeks after intervention., change from baseline at 1.5 months reported
Goal Attainment Scale (GAS)
The Goal Attainment Scale (GAS) is a measure of participants' individual goals that could be achieved in the course of intervention. Each goal will be rated on a 5-point scale ranging from -2 to +2 (maximum +2, minimum -2, the higher score indicates a better outcome. ) These attainment levels were combined in a single T-score by applying the formula recommended by Kiresuk \& Sherman, which accounts for variable numbers of goals, inter-correlation of goal areas and variable weighting: Total score = 50 +{(10Σ(wi xi ))/(0.7Σwi 2 + 0.3(Σwi )2 )½} where wi =weight assigned to the ith goal and xi = the score of the ith goal. In the first session, the therapist will discuss with the participants and their families to define the goals. In the last session, the therapist use the GAS to qualify interpretation results. The outcome is measured at 4 time points: 1 week before intervention, 5 weeks after injection (in the middle of intervention), post-intervention, 6 weeks after intervention.
Time frame: assessed at 1 week before intervention, 5 weeks after injection (in the middle of intervention), 1 week after intervention (post-intervention), 6 weeks after intervention., change from baseline at 1.5 months reported
| Milestone | Condensed RT Group | Distributed RT Group |
|---|---|---|
| Started | 18 | 18 |
| Completed | 18 | 18 |
| Not completed | 0 | 0 |
The upper-extremity (UE) subscale of the FMA will be used to assess neuromusculoskeletal and movement related functions. It consists of 33 upper extremity items for the reflexes and movement of shoulder, elbow, forearm, wrist, hand, and coordination/speed. They are scored on a 3-point ordinal scale (0-cannot perform, 1-performs partially, 2-performs fully)(Fugl Meyer et al., 1975). Higher score indicates better motor function of UE. The maximum score is 66, and the minimum score is 0. Satisfactory psychometric properties of the FMA have been demonstrated(Hsueh \& Hsieh, 2002;Platz et al., 2005). The outcome will be measured at 4 time points: 1 week before intervention, 5 weeks after injection (in the middle of intervention), 1 week after intervention (post-intervention), 6 weeks after intervention.
| score on a scale | Condensed RT Group | Distributed RT Group |
|---|---|---|
| Fugl-Meyer Assessment (FMA) | 3.45 ± 4.22 | 1.94 ± 2.29 |
The WMFT is a quantitative measure of upper extremity motor ability through timed and functional tasks. The WMFT includes 17 tasks (15 function-based and 2 strength-based). In this study only 15 function-based tasks were used. Performances were timed and rated by using a 6-point ordinal scale ranging from 0 to 5 ,There are 2 different scores: the WMFT -Time (time required to complete the tasks) and WMFT -FAS (functional Ability Scale, where a score of 6 points is used to assess the functional capacity of each task: 0 indicating that the patient cannot attempt the task, and 5 where the movement seems normal) The item ratings and time are summed respectively, and the average item rating and time are reported.The minimum value of mean FAS is 0, maximum 5, the higher the better. The outcome will be measured at 4 time points: 1 week before intervention, 5 weeks after injection (in the middle of intervention), 1 week after intervention (post-intervention), 6 weeks after in
| seconds | Condensed RT Group | Distributed RT Group |
|---|---|---|
| Wolf Motor Function Test (WMFT)-Time | -6.31 ± 2.29 | -7.89 ± 3.24 |
Spasticity of skeletal muscle in upper extremity will be evaluated by using the MAS scale (Bohannon \& Smith, 1987). It uses a 6-level scale to score the average resistance to passive movement for each join with higher score indicating higher spasticity. The MAS has shown good reliability and validity (Pandyan et al., 1999). The maximum of MAS scale is 4, and the minimum is 0. The outcome will be measured at 4 time points: 1 week before intervention, 5 weeks after injection (in the middle of intervention), post intervention, 6 weeks after intervention.
| score on a scale | Condensed RT Group | Distributed RT Group |
|---|---|---|
| Proximal | 0.98 ± 0.33 | 1.07 ± 0.48 |
| Distal | 1.10 ± 0.55 | 1.43 ± 0.50 |
The WMFT is a quantitative measure of upper extremity motor ability through timed and functional tasks. The WMFT includes 17 tasks (15 function-based and 2 strength-based). In this study only 15 function-based tasks were used. Performances were timed and rated by using a 6-point ordinal scale ranging from 0 to 5 ,There are 2 different scores: the WMFT -Time (time required to complete the tasks) and WMFT -FAS (functional Ability Scale, where a score of 6 points is used to assess the functional capacity of each task: 0 indicating that the patient cannot attempt the task, and 5 where the movement seems normal) The item ratings and time are summed respectively, and the average item rating and time are reported.The minimum value of mean FAS is 0, maximum 5, the higher the better. The outcome will be measured at 4 time points: 1 week before intervention, 5 weeks after injection (in the middle of intervention), 1 week after intervention (post-intervention), 6 weeks after in
| score on a scale | Condensed RT Group | Distributed RT Group |
|---|---|---|
| Wolf Motor Function Test (WMFT)-Function | 2.32 ± 0.48 | 2.20 ± 0.39 |
The COPM, a semi-structured interview, will be used to assess a participant's perception of the performance in the areas of self-care, productivity and leisure (Dedding, Cardol, Eyssen, \& Beelen, 2004). The COPM can capture information about activities that the participant wants, needs or is expected to perform. The participant will be asked to rate five most important activities on a 10-point scale for performance, ranging from 1 (not at all able) to 10 (able to perform extremely well), and for satisfaction, ranging from 1 (not at all satisfied) to 10 (extremely satisfied)(Dedding et al.,2004). The COPM is a reliable, valid, and responsive outcome measure for practitioners and researchers (Carswell et al., 2004). The outcome will be measured at 4 time points: 1 week before intervention, 5 weeks after injection (in the middle of intervention), 1 week after intervention (post-intervention), 6 weeks after intervention.
| score on a scale | Condensed RT Group | Distributed RT Group |
|---|---|---|
| Performance | 5.60 ± 1.86 | 5.45 ± 1.96 |
| Satisfication | 5.94 ± 2.16 | 5.45 ± 2.1 |
The Goal Attainment Scale (GAS) is a measure of participants' individual goals that could be achieved in the course of intervention. Each goal will be rated on a 5-point scale ranging from -2 to +2 (maximum +2, minimum -2, the higher score indicates a better outcome. ) These attainment levels were combined in a single T-score by applying the formula recommended by Kiresuk \& Sherman, which accounts for variable numbers of goals, inter-correlation of goal areas and variable weighting: Total score = 50 +{(10Σ(wi xi ))/(0.7Σwi 2 + 0.3(Σwi )2 )½} where wi =weight assigned to the ith goal and xi = the score of the ith goal. In the first session, the therapist will discuss with the participants and their families to define the goals. In the last session, the therapist use the GAS to qualify interpretation results. The outcome is measured at 4 time points: 1 week before intervention, 5 weeks after injection (in the middle of intervention), post-intervention, 6 weeks after intervention.
| T score | Condensed RT Group | Distributed RT Group |
|---|---|---|
| Goal Attainment Scale (GAS) | 47.11 ± 7.90 | 51.83 ± 6.92 |
Collected over All-Cause Mortality, Serious, and Other [Not Including Serious] Adverse Events were not monitored/assessed. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Condensed RT Group | — | — | — |
| Distributed RT Group | — | — | — |
| Age, Categorical(Participants) | Condensed RT Group | Distributed RT Group | Total |
|---|---|---|---|
| <=18 years | 0 | 0 | 0 |
| Between 18 and 65 years | 18 | 18 | 36 |
| >=65 years | 0 | 0 | 0 |
| Age, Continuous(years) | Condensed RT Group | Distributed RT Group | Total |
|---|---|---|---|
| Mean | 51.73 ± 13.21 | 53 ± 8.27 | 52.36 ± 10.88 |
| Sex: Female, Male(Participants) | Condensed RT Group | Distributed RT Group | Total |
|---|---|---|---|
| Female | 4 | 3 | 7 |
| Male | 14 | 15 | 29 |
| Race/Ethnicity, Customized(Participants) | Condensed RT Group | Distributed RT Group | Total |
|---|---|---|---|
| Asia | 18 | 18 | 36 |
| Region of Enrollment(participants) | Condensed RT Group | Distributed RT Group | Total |
|---|---|---|---|
| Taiwan | 18 | 18 | 36 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Oct 2017 to primary completion in May 2019, 19 months.
Results were first posted in Jun 2020, 1 year 1 month after primary completion.
Of 3,117 non-industry interventional studies with no phase under Stroke, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 46. This study's 19 months is below that.
Counting every sponsor, half of 3,261 studies reached it within 23 months; a quarter within 10 and three quarters within 46.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Aug 2018. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Chang Gung Memorial Hospital →